Apr 7 |
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
Mar 27 |
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
|
Mar 22 |
BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident
|
Mar 20 |
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
Mar 6 |
BridgeBio prices $250M stock offering
|
Mar 6 |
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
|
Mar 5 |
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
|
Mar 4 |
BridgeBio Pharma proposes underwritten offering of common stock
|
Mar 4 |
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
|
Mar 4 |
Bayer acquires European marketing rights for cardio drug Acoramidis
|